Symbols / IMNN $3.14 -2.48% Imunon, Inc.
IMNN Chart
About
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.32M |
| Enterprise Value | 1.64M | Income | -14.49M | Sales | — |
| Book/sh | 2.42 | Cash/sh | 3.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.00 | PEG | — |
| P/S | — | P/B | 1.30 | P/C | — |
| EV/EBITDA | -0.11 | EV/Sales | — | Quick Ratio | 1.90 |
| Current Ratio | 2.32 | Debt/Eq | 14.27 | LT Debt/Eq | — |
| EPS (ttm) | -6.83 | EPS next Y | -3.14 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 08:00 | ROA | -83.22% |
| ROE | -256.41% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.92M |
| Shs Float | 2.59M | Short Float | 6.14% | Short Ratio | 10.83 |
| Short Interest | — | 52W High | 41.22 | 52W Low | 2.52 |
| Beta | — | Avg Volume | 92.95K | Volume | 29.36K |
| Target Price | $21.50 | Recom | Strong_buy | Prev Close | $3.22 |
| Price | $3.14 | Change | -2.48% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-19 | down | D. Boral Capital | Buy → Hold | — |
| 2025-05-13 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-05-07 | main | D. Boral Capital | Buy → Buy | $29 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-03-24 | main | D. Boral Capital | Buy → Buy | $29 |
| 2025-02-27 | main | D. Boral Capital | Buy → Buy | $29 |
| 2025-02-19 | main | D. Boral Capital | Buy → Buy | $29 |
| 2025-01-24 | main | D. Boral Capital | Buy → Buy | $29 |
| 2024-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-19 | main | D. Boral Capital | Buy → Buy | $29 |
| 2024-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-10 | main | D. Boral Capital | Buy → Buy | $29 |
| 2024-11-25 | main | D. Boral Capital | Buy → Buy | $29 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-07 | main | EF Hutton | Buy → Buy | $29 |
| 2024-10-31 | main | EF Hutton | Buy → Buy | $29 |
| 2024-09-23 | init | EF Hutton | — → Buy | $29 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-05 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-05-14 | main | HC Wainwright & Co. | Buy → Buy | $12 |
- Imunon, Inc. (NASDAQ:IMNN) Q4 2025 Earnings Call Transcript - MSN Mon, 06 Apr 2026 13
- IMUNON says ovarian cancer therapy added 14.7 months survival - Stock Titan ue, 31 Mar 2026 12
- IMUNON ($IMNN) Releases Q4 2025 Earnings - Quiver Quantitative ue, 31 Mar 2026 14
- Imunon Expands At-The-Market Equity Offering Capacity - The Globe and Mail ue, 24 Mar 2026 07
- IMUNON INC (NASDAQ:IMNN) Reports Q4 2025 Results with Focus on Phase 3 Progress for IMNN-001 - ChartMill ue, 31 Mar 2026 16
- Imunon Earnings Call: Strong Data, Tight Cash Runway - TipRanks Sat, 04 Apr 2026 00
- Imunon stock rises following strategic restructuring to focus on Phase 3 trial - Investing.com hu, 05 Feb 2026 08
- ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Clinical Trials Arena Wed, 04 Jun 2025 07
- IMUNON to outline 2025 results and IMNN-001 update March 31 - Stock Titan ue, 24 Mar 2026 07
- IMUNON, Inc. Advances Enrollment in Phase 3 OVATION 3 Study, Paving the Way for Future BLA Filing and Potential Breakthrough in Ovarian Cancer Treatment | IMNN Stock News - Quiver Quantitative Mon, 29 Dec 2025 08
- With PARP therapy, women on IMUNON lived 24.2 months longer - Stock Titan Wed, 25 Mar 2026 07
- Ovarian cancer trial enrollment speeds up as IMUNON trims staff - Stock Titan hu, 05 Feb 2026 08
- IMUNON (IMNN) highlights 2025 loss reduction and strong IMNN-001 survival data - Stock Titan ue, 31 Mar 2026 12
- Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M - Stock Titan Mon, 23 Mar 2026 07
- IMUNON (NASDAQ: IMNN) posts OVATION data: 13-month OS gain; IMNN-001 in Phase 3 - Stock Titan Mon, 10 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.50
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.50
|
| Operating Expense |
|
14.65
-23.42%
|
19.13
-9.02%
|
21.03
-17.27%
|
25.42
|
| Research And Development |
|
7.78
-33.15%
|
11.64
+3.12%
|
11.29
-3.80%
|
11.73
|
| Selling General And Administration |
|
6.87
-8.31%
|
7.49
-23.09%
|
9.74
-28.82%
|
13.69
|
| General And Administrative Expense |
|
6.87
-8.31%
|
7.49
-23.09%
|
9.74
-28.82%
|
13.69
|
| Other Gand A |
|
6.87
-8.31%
|
7.49
-23.09%
|
9.74
-28.82%
|
13.69
|
| Total Expenses |
|
14.65
-23.42%
|
19.13
-9.02%
|
21.03
-17.27%
|
25.42
|
| Operating Income |
|
-14.65
+23.42%
|
-19.13
+9.02%
|
-21.03
+15.61%
|
-24.92
|
| Total Operating Income As Reported |
|
-14.65
+23.42%
|
-19.13
+9.02%
|
-21.03
+15.61%
|
-24.92
|
| EBITDA |
|
-13.95
+24.23%
|
-18.41
+7.36%
|
-19.88
+37.30%
|
-31.71
|
| Normalized EBITDA |
|
-14.11
+25.46%
|
-18.93
+5.28%
|
-19.98
+15.64%
|
-23.69
|
| Reconciled Depreciation |
|
0.70
-2.68%
|
0.72
-0.26%
|
0.72
-1.59%
|
0.73
|
| EBIT |
|
-14.65
+23.42%
|
-19.13
+7.12%
|
-20.60
+36.50%
|
-32.44
|
| Total Unusual Items |
|
0.16
-69.61%
|
0.51
+399.02%
|
0.10
+101.28%
|
-8.02
|
| Total Unusual Items Excluding Goodwill |
|
0.16
-69.61%
|
0.51
+399.02%
|
0.10
+101.28%
|
-8.02
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.33
+95.87%
|
-7.97
|
| Other Special Charges |
|
—
|
—
|
0.33
|
—
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
13.37
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.00
+100.00%
|
-5.40
|
| Net Income |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Pretax Income |
|
-14.50
+22.15%
|
-18.62
+10.46%
|
-20.80
+44.49%
|
-37.47
|
| Net Non Operating Interest Income Expense |
|
—
|
0.45
-14.85%
|
0.53
+111.68%
|
-4.53
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
0.20
-96.08%
|
5.03
|
| Net Interest Income |
|
—
|
0.45
-14.85%
|
0.53
+111.68%
|
-4.53
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
0.20
-96.08%
|
5.03
|
| Interest Income Non Operating |
|
—
|
0.45
-37.97%
|
0.73
+44.42%
|
0.50
|
| Interest Income |
|
—
|
0.45
-37.97%
|
0.73
+44.42%
|
0.50
|
| Other Income Expense |
|
0.16
-69.61%
|
0.51
+274.41%
|
-0.29
+96.34%
|
-8.02
|
| Other Non Operating Income Expenses |
|
—
|
—
|
-0.40
-22105.50%
|
0.00
|
| Gain On Sale Of Security |
|
0.16
-69.61%
|
0.51
+18.62%
|
0.43
+977.25%
|
-0.05
|
| Tax Provision |
|
—
|
0.00
+100.00%
|
-1.28
+18.29%
|
-1.57
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
+48.78%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
-100.00%
|
0.01
+101.90%
|
-0.33
|
| Net Income Including Noncontrolling Interests |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Net Income From Continuing Operation Net Minority Interest |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Net Income From Continuing And Discontinued Operation |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Net Income Continuous Operations |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Normalized Income |
|
-14.65
+23.42%
|
-19.13
+2.44%
|
-19.61
+30.47%
|
-28.21
|
| Net Income Common Stockholders |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Diluted EPS |
|
-6.83
+67.68%
|
-21.13
+25.00%
|
-28.17
+57.06%
|
-65.61
|
| Basic EPS |
|
-6.83
+67.68%
|
-21.13
+25.00%
|
-28.17
+57.06%
|
-65.61
|
| Basic Average Shares |
|
2.12
+140.67%
|
0.88
+27.23%
|
0.69
+26.63%
|
0.55
|
| Diluted Average Shares |
|
2.12
+140.67%
|
0.88
+27.23%
|
0.69
+26.63%
|
0.55
|
| Diluted NI Availto Com Stockholders |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
12.29
+26.46%
|
9.72
-55.67%
|
21.92
-50.16%
|
43.98
|
| Current Assets |
|
10.72
+33.90%
|
8.01
-56.09%
|
18.24
-50.41%
|
36.78
|
| Cash Cash Equivalents And Short Term Investments |
|
8.78
+49.52%
|
5.87
-62.58%
|
15.70
-52.07%
|
32.75
|
| Cash And Cash Equivalents |
|
8.78
+49.52%
|
5.87
+0.59%
|
5.84
-49.20%
|
11.49
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
9.86
-53.62%
|
21.25
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Accrued Interest Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
1.50
|
| Other Current Assets |
|
1.94
-9.06%
|
2.14
-16.06%
|
2.55
+5.89%
|
2.40
|
| Total Non Current Assets |
|
1.56
-8.43%
|
1.71
-53.54%
|
3.68
-48.90%
|
7.20
|
| Net PPE |
|
1.51
-8.69%
|
1.66
-29.34%
|
2.35
+233.29%
|
0.70
|
| Gross PPE |
|
2.79
-2.26%
|
2.85
-35.84%
|
4.45
+32.90%
|
3.35
|
| Accumulated Depreciation |
|
-1.28
-6.66%
|
-1.20
+43.10%
|
-2.10
+20.48%
|
-2.64
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.11
-1.15%
|
1.12
-50.22%
|
2.25
-20.28%
|
2.82
|
| Other Properties |
|
0.98
-11.88%
|
1.12
-29.96%
|
1.60
+923.30%
|
0.16
|
| Leases |
|
0.70
+13.11%
|
0.62
+1.97%
|
0.61
+62.66%
|
0.37
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
0.00
|
| Goodwill |
|
—
|
—
|
—
|
—
|
| Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
1.28
-18.29%
|
1.57
|
| Non Current Deferred Taxes Assets |
|
—
|
0.00
-100.00%
|
1.28
-18.29%
|
1.57
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
0.05
+0.00%
|
0.05
+0.00%
|
0.05
-98.98%
|
4.92
|
| Total Liabilities Net Minority Interest |
|
5.23
-4.51%
|
5.47
-35.84%
|
8.53
-41.76%
|
14.65
|
| Current Liabilities |
|
4.62
-3.39%
|
4.79
-35.24%
|
7.39
-26.36%
|
10.04
|
| Payables And Accrued Expenses |
|
4.22
-2.68%
|
4.33
-37.24%
|
6.91
-17.61%
|
8.38
|
| Payables |
|
1.39
+7.14%
|
1.30
-63.02%
|
3.52
-1.99%
|
3.59
|
| Accounts Payable |
|
1.39
+7.14%
|
1.30
-63.02%
|
3.52
-1.99%
|
3.59
|
| Other Payable |
|
—
|
—
|
1.44
-34.33%
|
2.20
|
| Current Accrued Expenses |
|
2.82
-6.89%
|
3.03
-10.52%
|
3.39
-29.29%
|
4.79
|
| Current Debt And Capital Lease Obligation |
|
0.41
-10.17%
|
0.45
-6.81%
|
0.49
-70.68%
|
1.66
|
| Current Debt |
|
—
|
—
|
—
|
1.42
|
| Other Current Borrowings |
|
—
|
—
|
—
|
1.42
|
| Current Capital Lease Obligation |
|
0.41
-10.17%
|
0.45
-6.81%
|
0.49
+110.37%
|
0.23
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.60
-12.30%
|
0.69
-39.71%
|
1.14
-75.29%
|
4.61
|
| Long Term Debt And Capital Lease Obligation |
|
0.60
-12.30%
|
0.69
-39.71%
|
1.14
-75.29%
|
4.61
|
| Long Term Debt |
|
—
|
—
|
—
|
4.61
|
| Long Term Capital Lease Obligation |
|
0.60
-12.30%
|
0.69
-39.71%
|
1.14
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-54.35%
|
29.33
|
| Common Stock Equity |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-54.35%
|
29.33
|
| Capital Stock |
|
0.03
+253.75%
|
0.01
-89.72%
|
0.09
+26.41%
|
0.07
|
| Common Stock |
|
0.03
+253.75%
|
0.01
-89.72%
|
0.09
+26.41%
|
0.07
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
3.42
+207.60%
|
1.11
+54.27%
|
0.72
+26.41%
|
0.57
|
| Ordinary Shares Number |
|
3.42
+207.60%
|
1.11
+54.27%
|
0.72
+26.41%
|
0.57
|
| Treasury Shares Number |
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
428.41
+4.21%
|
411.12
+2.40%
|
401.50
+0.88%
|
397.98
|
| Retained Earnings |
|
-421.30
-3.56%
|
-406.80
-4.80%
|
-388.18
-5.29%
|
-368.67
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
-100.00%
|
0.06
+129.47%
|
0.03
|
| Treasury Stock |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
|
| Other Equity Adjustments |
|
—
|
—
|
0.06
+129.47%
|
0.03
|
| Total Equity Gross Minority Interest |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-54.35%
|
29.33
|
| Total Capitalization |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-60.55%
|
33.94
|
| Working Capital |
|
6.10
+89.27%
|
3.22
-70.30%
|
10.85
-59.43%
|
26.74
|
| Invested Capital |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-62.14%
|
35.36
|
| Total Debt |
|
1.01
-11.46%
|
1.14
-29.88%
|
1.62
-74.07%
|
6.27
|
| Capital Lease Obligations |
|
1.01
-11.46%
|
1.14
-29.88%
|
1.62
+604.10%
|
0.23
|
| Net Tangible Assets |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-54.35%
|
29.33
|
| Tangible Book Value |
|
7.06
+66.39%
|
4.24
-68.30%
|
13.39
-54.35%
|
29.33
|
| Interest Payable |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.90
+26.30%
|
-18.85
+0.88%
|
-19.02
+17.64%
|
-23.10
|
| Cash Flow From Continuing Operating Activities |
|
-13.90
+26.30%
|
-18.85
+0.88%
|
-19.02
+17.64%
|
-23.10
|
| Net Income From Continuing Operations |
|
-14.50
+22.15%
|
-18.62
+4.58%
|
-19.51
+45.64%
|
-35.90
|
| Depreciation Amortization Depletion |
|
0.70
-2.68%
|
0.72
-0.26%
|
0.72
-1.59%
|
0.73
|
| Depreciation |
|
0.70
-2.68%
|
0.72
-0.26%
|
0.72
-1.59%
|
0.73
|
| Depreciation And Amortization |
|
0.70
-2.68%
|
0.72
-0.26%
|
0.72
-1.59%
|
0.73
|
| Other Non Cash Items |
|
0.10
|
—
|
0.06
+100.96%
|
-5.71
|
| Stock Based Compensation |
|
0.13
-73.31%
|
0.48
-37.12%
|
0.76
-71.60%
|
2.67
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.38
-97.19%
|
13.37
|
| Deferred Tax |
|
0.00
-100.00%
|
1.28
+346.69%
|
0.29
+256.14%
|
-0.18
|
| Deferred Income Tax |
|
0.00
-100.00%
|
1.28
+346.69%
|
0.29
+256.14%
|
-0.18
|
| Operating Gains Losses |
|
—
|
-0.06
-117.05%
|
0.36
+954.49%
|
0.03
|
| Gain Loss On Investment Securities |
|
—
|
-0.06
-280.70%
|
0.03
-0.48%
|
0.03
|
| Change In Working Capital |
|
-0.33
+87.63%
|
-2.65
-28.17%
|
-2.07
-209.09%
|
1.89
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.07
+439.19%
|
-0.02
|
| Change In Prepaid Assets |
|
0.19
-52.67%
|
0.41
+388.70%
|
-0.14
-422.01%
|
0.04
|
| Change In Payables And Accrued Expense |
|
-0.52
+82.96%
|
-3.06
-53.41%
|
-1.99
-194.37%
|
2.11
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
1.07
|
| Change In Payable |
|
—
|
—
|
—
|
1.04
|
| Change In Account Payable |
|
—
|
—
|
—
|
1.04
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.50
|
| Change In Other Current Assets |
|
—
|
—
|
0.00
+100.00%
|
-0.24
|
| Investing Cash Flow |
|
-0.28
-102.85%
|
9.83
-10.70%
|
11.01
+32.91%
|
8.28
|
| Cash Flow From Continuing Investing Activities |
|
-0.28
-102.85%
|
9.83
-10.70%
|
11.01
+32.91%
|
8.28
|
| Net PPE Purchase And Sale |
|
-0.28
-849.77%
|
-0.03
+93.46%
|
-0.45
-68.69%
|
-0.27
|
| Purchase Of PPE |
|
-0.28
-849.77%
|
-0.03
+93.46%
|
-0.45
-68.69%
|
-0.27
|
| Capital Expenditure |
|
-0.28
-849.77%
|
-0.03
+93.46%
|
-0.45
-68.69%
|
-0.27
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
9.86
-13.96%
|
11.46
+34.04%
|
8.55
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-0.06
+99.58%
|
-13.54
+71.92%
|
-48.23
|
| Sale Of Investment |
|
0.00
-100.00%
|
9.92
-60.34%
|
25.00
-55.97%
|
56.77
|
| Financing Cash Flow |
|
17.09
+88.57%
|
9.06
+349.01%
|
-3.64
-154.12%
|
6.72
|
| Cash Flow From Continuing Financing Activities |
|
17.09
+88.57%
|
9.06
+349.01%
|
-3.64
-154.12%
|
6.72
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-6.42
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-6.42
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-6.42
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-6.42
|
0.00
|
| Net Common Stock Issuance |
|
13.63
+50.41%
|
9.06
+225.75%
|
2.78
-58.63%
|
6.72
|
| Common Stock Dividend Paid |
|
-0.01
|
0.00
|
—
|
—
|
| Cash Dividends Paid |
|
-0.01
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-28.50
|
| Proceeds From Stock Option Exercised |
|
3.47
|
0.00
|
—
|
0.00
|
| Changes In Cash |
|
2.91
+8403.53%
|
0.03
+100.29%
|
-11.65
-44.00%
|
-8.09
|
| Beginning Cash Position |
|
5.87
+0.59%
|
5.84
-66.62%
|
17.49
-31.63%
|
25.59
|
| End Cash Position |
|
8.78
+49.52%
|
5.87
+0.59%
|
5.84
-66.62%
|
17.49
|
| Free Cash Flow |
|
-14.18
+24.93%
|
-18.88
+3.03%
|
-19.47
+16.65%
|
-23.36
|
| Interest Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
0.18
-96.30%
|
4.85
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
+25.00%
|
0.00
|
| Common Stock Issuance |
|
13.63
+50.41%
|
9.06
+225.75%
|
2.78
-58.63%
|
6.72
|
| Issuance Of Capital Stock |
|
13.63
+50.41%
|
9.06
+225.75%
|
2.78
-92.10%
|
35.22
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
28.50
|
| Preferred Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-28.50
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-23 View
- 8-K2026-02-05 View
- 8-K2026-01-07 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 8-K2025-12-31 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 42025-09-09 View
- 8-K2025-08-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|